All In Biotech

NDA 218160 · Eli Lilly and CO

Retevmo

Selpercatinib · Oral · Kinase Inhibitor

Orphan

Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Apr 10, 2024

Approved uses

6

Original approval plus efficacy supplements

Registered trials

37

3 Phase 3, 5 recruiting

FAERS reports

1,395

1,084 serious, 208 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 11, 2026.

RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test ( 1.1 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) ( 1.3 ) Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options ( 1.4 ) 1.1 RET Fusion-Positive Non-Small Cell Lung Cancer RETEVMO ® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test. 1.2 RET -Mutant Medullary Thyroid Cancer RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. 1.3 RET Fusion-Positive Thyroid Cancer RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected...

Mechanism: Selpercatinib is a kinase inhibitor. Selpercatinib inhibited wild-type RET and multiple mutated RET isoforms as well as VEGFR1 and VEGFR3 with IC 50 values ranging from 0.92 nM to 67.8 nM. In other enzyme assays, selpercatinib also inhibited FGFR 1, 2, and 3 at higher concentrations that were still clinically achievable. In cellular assays, selpercatinib inhibited RET at approximately 60-fold lower concentrations than FGFR1 and 2 and approximately 8-fold lower concentration than VEGFR3. Certain point mutations in RET or chromosomal rearrangements involving in-frame fusions of RET with various...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 14, 2026 Supplement 7 · Efficacy OrphanLetterLabel
  • Nov 20, 2025 Supplement 6 · Efficacy · priority review OrphanLetterLabel
  • Sep 27, 2024 Supplement 3 · Efficacy OrphanLetterLabel
  • Sep 27, 2024 Supplement 2 · Efficacy · priority review OrphanLetterLabel
  • Jun 12, 2024 Supplement 1 · Efficacy OrphanLabelLetter
  • Apr 10, 2024 Original approval · Type 3 - New Dosage Form OrphanLabelLetterReview
6 products under this application
  • RETEVMO · SELPERCATINIB 40MG · CAPSULE, ORAL · Prescription
  • RETEVMO · SELPERCATINIB 120MG · TABLET, ORAL · Prescription
  • RETEVMO · SELPERCATINIB 40MG · TABLET, ORAL · Prescription
  • RETEVMO · SELPERCATINIB 80MG · CAPSULE, ORAL · Prescription
  • RETEVMO · SELPERCATINIB 160MG · TABLET, ORAL · Prescription
  • RETEVMO · SELPERCATINIB 80MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Selpercatinib" as an intervention, any sponsor and status, largest first.

All 37 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malignant neoplasm progression136
  • death114
  • diarrhoea72
  • hypertension70
  • fatigue68
  • hypersensitivity65
  • rash61
  • pyrexia50
  • hepatic function abnormal49
  • alanine aminotransferase increased42
  • aspartate aminotransferase increased42
  • off label use41

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202082
2021164
2022214
2023217
2024302
2025206
2026210

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Retevmo (Selpercatinib)

2024 spending

$84.9M

Beneficiaries

656

4,801 claims

Per beneficiary

$129,402

$179.43 per unit

View as table
YearSpending
2020$6,896,189
2021$26,343,353
2022$44,178,814
2023$57,651,230
2024$84,887,654

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 33 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.